TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
 Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK) - EconoTimes)
PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will host a live teleconference and webcast at 10:00 a.m. Eastern Time (3:00 p.m. GMT) today (Tuesday February 2, 2016) to discuss the expansion of their strategic collaboration with GSK and the acceleration of the NY-ESO program.
The live webcast of the conference call will be made available via Adaptimmune’s corporate website at www.adaptimmune.com on the events page. An archive will be available after the call at the same address.
To participate in the live conference call, if preferred, please dial (877) 280-2296 (U.S.) or +44 (0)20 7136 2056 or 0800 279 4992 (United Kingdom). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (5656147).
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com.
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: [email protected]
